Skip to main
  1. Stocks
  2. Aldeyra Therapeutics
  3. Forecast
ALDX

Aldeyra Therapeutics (ALDX) Stock Forecast & Price Target

Aldeyra Therapeutics (ALDX) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Aldeyra Therapeutics is viewed favorably because Reproxalap has shown compelling activity across nine adequate and well-controlled trials, with five meeting all multiplicity-controlled primary endpoints, while the FDA dispute remains centered on interpretation rather than a request for new studies. The company’s RASP platform and first-mover work on irreversible scavengers create a differentiated pipeline spanning dry eye disease, allergic conjunctivitis, and other inflammatory disorders, supported by large underserved markets and a strategy to conserve resources by continuing ADX-2191 only in primary vitreoretinal lymphoma. Financially, the current operational cash runway is anticipated to last into 2029, and management expects ABBV could execute the licensing agreement if Reproxalap is ultimately approved.

Bears say

Aldeyra Therapeutics is facing a deeply challenged regulatory path for reproxalap, with the FDA issuing a CRL on April 3, 2025, and another CRL today after repeated resubmissions failed to convince regulators of efficacy. The company’s reliance on a single chamber trial, despite a field trial and later FDA requests for additional study documentation, underscores inconsistent clinical results and methodological concerns rather than a durable evidentiary package. With no approved product revenue highlighted and a pipeline still dependent on early- and late-stage candidates such as ADX248, ADX743, and ADX2191, the fundamental risk remains high because future value is heavily tied to uncertain clinical and regulatory outcomes.

Aldeyra Therapeutics (ALDX) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aldeyra Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Aldeyra Therapeutics (ALDX) Analyst Forecast & Price Prediction

Get the latest Aldeyra Therapeutics (ALDX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aldeyra Therapeutics (ALDX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aldeyra Therapeutics (ALDX) Forecast

Analysts have given Aldeyra Therapeutics (ALDX) a Buy based on their latest research and market trends.

According to 2 analysts, Aldeyra Therapeutics (ALDX) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aldeyra Therapeutics (ALDX)


Aldeyra Therapeutics (ALDX) Analyst Forecast & Price Prediction

Get the latest Aldeyra Therapeutics (ALDX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aldeyra Therapeutics (ALDX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ALDX stock data and trends